Transdermal drug delivery system for liquid active ingredient

Details Transdermal drug delivery system for liquid active ingredient Transdermal drug delivery system for liquid active ingredient

A - Human Necessities

61

K

A61K 47/06 (2006.01) A61K 9/70 (2006.01) A61K 31/131 (2006.01) A61K 31/137 (2006.01) A61K 31/27 (2006.01) A61K 47/14 (2006.01)

Patent

CA 2678320

A monolithic device for transdermal administration of an active pharmaceutical ingredient which is selected from propargylamines and rivastigmine and is liquid at 25°C, has an adhesive matrix layer which includes the active ingredient in an acrylic polymer pressure sensitive adhesive without cross-linker agent containing a metal atom, the adhesive having a shear value of between 1.5 and 15 hours, and further includes a non-volatile coadjuvant selected from squalene and triethylcitrate present in the layer in an amount of 1 to 15wt%. The combination provides good release of the drug in use, reduces loss of the drug during a drying step in manufacture, reduces chemical interaction of the layer with the drug and achieves low level of skin irritation.

Affiliated with

Also associated with

Rating

Transdermal drug delivery system for liquid active ingredient does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdermal drug delivery system for liquid active ingredient, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal drug delivery system for liquid active ingredient will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1537385